MedTrace Logo

Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China

NCT02647554 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 347

Last updated 2022-10-13

No results posted yet for this study

Summary

A Prospective, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled, Trial of Ulinastatin Treatment in Adult Patients with Sepsis and Septic Shock in China

Conditions

Interventions

DRUG

ulinastatin

ulinastatin 400,000 IU every 8 hours for 10 days

DRUG

Placebo

matching placebo every 8 hours for 10 days

Sponsors & Collaborators

  • Techpool Bio-Pharma Co., Ltd.

    collaborator INDUSTRY

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Bin Du, MD · Peking Union Medical College Hospital, Beijing, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2021-05-01
Completion
2021-08-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02647554 on ClinicalTrials.gov